| Literature DB >> 32579991 |
Jun Fan1, Xiang Li1, Yong Gao2, Junjie Zhou1, Sihua Wang3, Bo Huang1, Junhua Wu1, Qin Cao1, Yajun Chen1, Zhenkao Wang1, Danju Luo1, Ting Zhou4, Ruiting Li4, You Shang4, Xiu Nie5.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32579991 PMCID: PMC7306202 DOI: 10.1016/j.jinf.2020.06.047
Source DB: PubMed Journal: J Infect ISSN: 0163-4453 Impact factor: 6.072
Demographic Characteristics of fatal Patients With COVID-19.
| Characteristics | |
|---|---|
| Median (IQR) age, years | 66 (60.75–77) |
| <40 years | 1 (5) |
| 40–60 years | 3 (15) |
| ≥60 years | 16 (80) |
| Sex | |
| Female | 6 (30) |
| Male | 14 (70) |
| Huanan Seafood Market exposure | 1 (5) |
| Initial common symptoms | |
| Fever | 15 (75) |
| Cough | 15 (75) |
| dyspnea | 10 (50) |
| Chest pain | 1 (5) |
| Headache | 1 (5) |
| Vomiting | 1 (5) |
| Diarrhoea | 4 (20) |
| Fatigue or myalgia | 10 (50) |
| Chest imaging, infiltratea | |
| Unilateral | 0 (0) |
| Bilateral | 20 (100) |
| Comorbidities | |
| Hypertension | 9 (45) |
| Diabetes | 2 (10) |
| Cardiovascular disease | 10 (50) |
| Chronic lung diseases | 1 (5) |
| Chronic kidney disease | 2 (10) |
| Malignancy | 7 (35) |
| Median (IQR) time from onset of symptom to hospital admission, days | 10 (6.75–14) |
| Median (IQR) time from hospital admission to death, days | 23 (20–30) |
| Vital signs on admission | |
| Disorders of consciousness | 0 (0) |
| Median (IQR) arterial pressure, mm Hg | 137 (120–150) |
| Median (IQR) heart rate, beat per minute | 91 (79–103) |
| Median (IQR) respiratory rate, breaths per minute | 25 (20–30) |
| Median (IQR) percutaneous oxygen saturation, | 92% (86.8%−97.3%) |
| Complications | |
| Sepsis | 18 (90) |
| Respiratory failure | 20 (100) |
| Acute respiratory distress syndrome | 14 (70) |
| Liver dysfunction | 17 (85) |
| Acute kidney injury | 14 (70) |
| Acute cardiac injury | 12 (60) |
| Treatment | |
| Antibacterial therapy | 20 (100) |
| Antiviral therapy | 20 (100) |
| Antifungal therapy | 12 (60) |
| Glucocorticoids therapy | 18 (90) |
| Intravenous immunoglobulin therapy | 11 (55) |
| Interferon inhalation | 3 (15) |
| Oxygen treatment | |
| High flow nasal cannula | 1 (5) |
| Noninvasive ventilation | 3 (15) |
| Invasive mechanical ventilation | 16 (80) |
| Continuous renal replacement therapy | 5 (25) |
| Extracorporeal membrane oxygenation | 0 (0) |
Fig. 1(A) Distribution of bacterial genera (OTUs) found in the lung samples of fatal COVID-19 patients defined by sequencing of the 16S rRNA gene. (B) Distribution of fungal genera (OTUs) found in the lung samples of fatal COVID-19 patients defined by sequencing of the ITS gene. Increasing depth of colour indicates the relative abundance of the OTU in an individual sample.